Novopulmon Novolizer (Budesonide)

Novopulmon Novolizer delivers budesonide directly to the airways, addressing inflammatory airway diseases.

• Asthma: improves lung function and reduces the frequency of exacerbations.
• Chronic obstructive pulmonary disease (COPD): decreases airway inflammation and helps maintain airflow.
• Allergic rhinitis: alleviates nasal congestion and inflammatory symptoms when used as part of a combined therapy regimen.

• Budesonide binds to glucocorticoid receptors in airway epithelial and inflammatory cells, modulating gene transcription to suppress pro‑inflammatory cytokines, reduce eosinophil activity, and increase anti‑inflammatory protein production, thereby decreasing airway inflammation and hyper‑responsiveness.

Adverse reactions may occur with inhaled budesonide, ranging from mild to serious.

Common Side Effects

• Oral candidiasis: fungal infection of the mouth.
• Hoarseness: voice changes after inhalation.
• Throat irritation: mild discomfort in the throat.
• Cough: transient coughing after use.
• Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects

• Paradoxical bronchospasm: worsening of breathing difficulty.
• Adrenal suppression: reduced cortisol production with high‑dose or prolonged use.
• Pneumonia: especially in patients with COPD.
• Severe hypersensitivity: anaphylaxis or angioedema.
• Osteoporosis: decreased bone mineral density with long‑term high‑dose therapy.

When using Novopulmon Novolizer, consider the following safety measures:

• Monitor lung function: regular assessment of respiratory status.
• Educate on technique: ensure correct inhaler use to minimise oral deposition.
• Review concomitant meds: assess for potential drug interactions.
• Assess infection risk: watch for signs of respiratory infections.
• Evaluate bone health: consider calcium and vitamin D supplementation for long‑term users.
• Store at ambient temperature: keep below 25°C, protect from moisture and direct sunlight.

Budesonide may interact with several drug classes; clinicians should evaluate the relevance of each interaction.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure.
• Systemic immunosuppressants: additive immunosuppression risk.

Moderate Interactions (Monitor Closely)

• Antifungal azoles: may modestly raise budesonide levels.
• Ritonavir: potential increase in systemic corticosteroid effects.
• Live vaccines: reduced vaccine efficacy due to immunosuppression.
• Diuretics: may enhance fluid retention when systemic exposure is high.
• Oral hypoglycaemic agents: possible alteration of glucose control.